Your session is about to expire
← Back to Search
MDMA-Assisted Psychotherapy for PTSD (MAPPUSX Trial)
MAPPUSX Trial Summary
This trial is studying whether MDMA (also known as “ecstasy”) can help relieve symptoms of post-traumatic stress disorder (PTSD). Researchers will give participants 3 doses of MDMA during 8 psychotherapy sessions over 12 weeks. They will measure the participants’ PTSD symptoms before and after the treatment period to see if MDMA helped.
MAPPUSX Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 100 Patients • NCT03537014MAPPUSX Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there other scientific investigations that have used MDMA as a test material?
"MDMA was first researched in 2021 by Dr. Simon Amar, LLC. So far, they have completed 34 studies and there are 9 more trials underway. A majority of these studies are being conducted in New york, New York."
What is the FDA's stance on MDMA?
"Although this is a Phase 3 trial, and thus there is some data supporting efficacy, MDMA was given a score of 3 due to the multiple rounds of data supporting safety."
Is this clinical trial taking place in several different hospitals throughout Canada?
"There are a total of 13 sites where this clinical trial is available, which include New york Private Practice in New York, UCSF in San Francisco, Aguazul-Blue Water Inc. in Boulder, and other locations."
Are patients able to enroll in this clinical trial at this time?
"This particular trial is no longer looking for patients. The original posting date was March 22, 2021 and the most recent update was on July 7, 2022. However, there are currently 325 studies actively admitting participants with post traumatic stress disorder (PTSD) and 9 trials for MDMA that are still looking for patients."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
Share this study with friends
Copy Link
Messenger